Prosonix, of Oxford, UK, has appointed Nigel Bell as executive chairman. A chemical engineer, Bell was most recently vice president of Infineum (UK), a Shell/ExxonMobil joint venture producing performance additives for the lubricant and fuels sector, and has worked in the global chemicals sector for 30 years.
Dr Chris Lee has been appointed business development director of Synexus with responsibility for the marketing and development of new and existing clients. Synexus, based in Manchester, is the largest multinational company in the recruitment and running of late stage clinical trials. Chris joins from Ajinomoto Pharmaceuticals, where he was medical director for the USA and Europe with responsibility for pre-clinical and clinical development and the management of all clinical trials in Europe and the US.
Leonard Kanavy joins Genentech as vice president of commercial operations. In this role, Kanavy will be responsible for leading the market planning, forecasting, sales operations, data acquisition and other groups. Kanavy joins the company from Novartis Pharmaceuticals, where he was vice president of commercial operations. Kanavy held several leadership roles at Novartis. Also at Genentech, Anthony Hurley has been promoted to vice president of fill/finish manufacturing. In this role, Hurley will continue to lead the South San Francisco commercial and clinical fill/finish operations, and will have overall responsibility for Genentech's future fill/finish facility in Hillsboro, Oregon, which is expected to be licensed and operational in 2010.
John Ratliff has been appointed as chief operating officer of Quintiles. Ratliff will be responsible for directing Quintiles' daily global operations and will report to chairman and ceo, Dennis Gillings. Ratliff has also been elected to the Quintiles board of directors. Prior to his appointment as coo, Ratliff had been Quintile's chief financial officer, the position he had held since joining the company in 2004, and before that served as cfo at Acterna.
Barbara Clarke is joining Archimedes Pharma as director of regulatory affairs. Barbara has over twenty years experience in regulatory affairs ranging from local affiliate work to global responsibilities in both small/medium and large pharmaceutical companies. Barbara joins Archimedes from Chiron where she spent the last seven years as regulatory affairs director. Matt Kennedy is joining the company as supply chain manager. Previously, Matt was materials manager in Shire Pharmaceutical's international supply chain group and was responsible for managing and developing a broad base of European contract manufacturers.